EUCTR2013-000517-20-FR进行中（未招募）1 期
A Phase 2, Open-Label Study of Rucaparib in Patients with Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1. Have signed an Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved informed consent form prior to any study-specific evaluation
- •2. Be =18 years of age at the time the informed consent form is signed
- •3. Have a histologically confirmed diagnosis of high-grade serous or Grade 2 or Grade 3 endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancer
- •- If mixed histology, >50% of the primary tumor must be confirmed to be high-grade serous or endometrioid upon re-review by local pathology
- •- Patients with a histology other than serous or endometrioid are also eligible for Part 2 of the study if they are known to harbor a deleterious/pathogenic BRCA mutation (germline or somatic)
- •4. Have relapsed/progressive disease as confirmed by radiologic assessment
- •5. Part 1: Received prior platinum-based therapy and have platinum-sensitive disease
- •a. Received =1 prior platinum-based treatment regimen; AND
- •b. Received a platinum-based regimen as their last treatment; continuous or switch maintenance treatment as part of this regimen is permitted (hormonal treatment may be permitted following the last platinum regimen with advance approval from the Sponsor); AND
- •c. Was sensitive to the last platinum regimen. Platinum-sensitive disease is defined as documented radiologic progression =6 months after the last dose of platinum administered in the treatment setting.
- •Part 2: Received at least 3, but no more than 4, prior chemotherapy
- •regimens and had documented treatment-free interval of =6 months
- •following 1st chemotherapy regimen received
- •a.Hormonal agents (eg. tamoxifen, letrozole, etc), anti-angiogenic
- •agents (eg. bevacizumab, pazopanib, cediranib, nintedanib, trebananib, etc), and other non-chemotherapy agents administered as single agent treatement will not be counted as a chemotherapy regimen for the purpose of determing patient eligibility
- •b.Agents administered in the maintenance setting will not be counted as a separate regimen
- •6. Part 1 only: If <55 years of age at diagnosis, or has prior history of breast cancer, or has close relative (first or second degree) with ovarian cancer or early onset (7. Have undergone a biopsy of tumor tissue prior to first dose of study drug and had the tumor tissue confirmed by the central laboratory as being of adequate quality
- •(at least 20% tumor content with a minimum of 80% nucleated cellular content). Note: biopsy is optional for Part 2 patients known to harbor a deleterious gBRCA mutation.
- •- If tumor tissue obtained from the biopsy is deemed inadequate, and the patient is unwilling or unable to have another biopsy, the patient may be considered for enrollment if archival tumor tissue is provided and deemed of adequate quality. This must occur prior to any treatment with rucaparib.
- •a. Biopsy must be of solid tumor tissue; ascites is not acceptable.
- •b. Biopsy must be of sufficient yield for planned analyses.
- •8. Have sufficient archival FFPE tumor tissue available for planned
- •analyses; cytospin blocks from ascites are not acceptable.
- •- ? The most recently obtained tumor tissue that is of adequate quality (at least 20% tumor content with a minimum of 80% nucleated cellular content) should be submitted
- •9. Have measurable disease as defined by RECIST v1.1 in additio
排除标准
- •1. Active second malignancy, i.e., patient known to have potentially fatal cancer present for which she may be (but not necessarily) currently receiving treatment
- •a. Patients with a history of malignancy that has been completely treated, with no evidence of that cancer currently, are permitted to enroll in the trial provided all chemotherapy was completed >6 months prior and/or bone marrow transplant (BMT) >2 years prior to first dose of rucaparib
- •2. Prior treatment with any PARP inhibitor, including oral or intravenous rucaparib. Patients who previously received iniparib are eligible
- •3. Symptomatic and/or untreated central nervous system (CNS) metastases. Patients with asymptomatic previously treated CNS metastases are eligible provided they have been clinically stable for at least 4 weeks
- •4. Pre-existing duodenal stent and/or any gastrointestinal disorder or defect that would, in the opinion of the Investigator, interfere with absorption of rucaparib
- •5. Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness, or history of chronic hepatitis B or C
- •6. Pregnant or breast feeding. Women of childbearing potential must have a negative serum pregnancy test <3 days prior to first dose of rucaparib.
- •7. Received treatment with chemotherapy, radiation, antibody therapy or other immunotherapy, gene therapy, vaccine therapy, angiogenesis inhibitors, or experimental drugs =14 days prior to first dose of rucaparib and/or ongoing adverse effects from such treatment > NCI CTCAE Grade 1 (ongoing Grade 2 non-hematologic toxicity related to most recent treatment regimen may be permitted with prior advanced approval from Sponsor).
- •8. Received administration of strong CYP1A2 or CYP3A4 inhibitors =7 days prior to first dose of rucaparib or have on-going requirements for these medications
- •9. Non-study related minor surgical procedure =5 days, or major surgical procedure =21
- •days, prior to first dose of rucaparib; in all cases, the patient must be sufficiently recovered and stable before treatment administration
- •10. Presence of any other condition that may increase the risk associated with study participation or may interfere with the interpretation of study results, and, in the opinion of the investigator, would make the patient inappropriate for entry into the study
- •11.Diagnosis of low-grade serous or Grade 1 endometrioid ovarian
- •12.Part 2 Only: Hospitalization for bowel obstruction within 3 months
- •prior to enrollment
研究者
相似试验
进行中（未招募）
1 期
A Phase 2, Open-Label Study of Rucaparib in Patients with Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerPlatinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerMedDRA version: 14.1 Level: PT Classification code 10061269 Term: Malignant peritoneal neoplasm System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1 Level: HLT Classification code 10016181 Term: Fallopian tube neoplasms malignant System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1 Level: PT Classification code 10033128 Term: Ovarian cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-000517-20-ESClovis Oncology, Inc.200
进行中（未招募）
1 期
A Phase 2, Open-Label Study of Rucaparib in Patients with Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerPlatinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerMedDRA version: 21.0 Level: PT Classification code 10061269 Term: Malignant peritoneal neoplasm System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: HLT Classification code 10016181 Term: Fallopian tube neoplasms malignant System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10033128 Term: Ovarian cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-000517-20-GBClovis Oncology, Inc.500
进行中（未招募）
1 期
Study of Rucaparib in Patients with Locally Advanced or Metastatic Urothelial Carcinomaocally Advanced Unresectable or Metastatic Urothelial CarcinomaMedDRA version: 20.0Level: LLTClassification code 10064467Term: Urothelial carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10044412Term: Transitional cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-004166-10-GBClovis Oncology, Inc.200
进行中（未招募）
1 期
Study of Rucaparib in Patients with Locally Advanced or Metastatic Urothelial Carcinomaocally Advanced Unresectable or Metastatic Urothelial CarcinomaMedDRA version: 21.0Level: PTClassification code 10044412Term: Transitional cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10064467Term: Urothelial carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-004166-10-ITCLOVIS ONCOLOGY, INC97
进行中（未招募）
1 期
Study of Rucaparib in Patients with Locally Advanced or Metastatic Urothelial CarcinomaEUCTR2017-004166-10-DEClovis Oncology, Inc.97